At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 8 enrolled
Drug / intervention
OP-101drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Open-Label Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 (Dendrimer N-acetyl-cysteine) After Subcutaneous Administration in Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating OP-101 for Healthy. Completed, enrolled 8 participants across 1 site.
Detailed Summary
A clinical study to measure the Safety, Tolerability, and Pharmacokinetics of OP-101 After Subcutaneous Administration in Healthy Volunteers
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesAustralia
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
Enrollment StartMar 2020
First PostedMar 2020
Primary CompletionMay 2020
TodayJul 2026
First PostedMar 26, 2020
Enrollment StartMar 19, 2020
Primary CompletionMay 22, 2020
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 6.3 years ago
Interventions
OP-101drug
Subcutaneous injection of OP-101 in healthy volunteers